Very cool! However, the amazing absence of results makes me question whether they've got a Nature letter forthcoming or whether they know that another AI lab has a similar finding...
Biosafety is a very real concern but "lab" is a big bucket, a molecular genetics lab can't synthesize new viruses out of thin air if it's not a virology lab. Sequencers sequence etc. The lab has the equipment it has.
This is great, but I can't help but wonder if we're going to have another post next week with a lab complaining that they were about to publish this same finding, and they had Claude proofread their paper, and whoops how'd that get into Anthropic's training data?
I wonder how long it will take for the damage Alpöge and Buckmaster have done to the perception of these AI-driven scientific developments to fade.
Not saying that they were right or wrong, but that single moment sullied all AI-driven breakthroughs that came after it, and I don't think it was ever particularly relevant, at least not nearly to the degree that it was presented in the media. But I guess it ended up being a convenient outlet for AI anxiety in the end.
I don't think of this stuff in terms of AI anxiety, I just think that the AI labs should be falling all over themselves to display deference and humility to those who made it possible.
The LLMs that make this stuff possible weren't created by the AI labs from whole cloth. They crept up and jumped onto the shoulders of giants, basically the collected (non-consensually, of course, but jingles keys look at this pelican riding a bicycle!) works of humanity. Every discovery LLMs enumerate in this fashion rightfully needs to have a billboard-sized asterisk regarding the provenance of the discovery. "Claude" didn't discover this, everyone who worked to produce the internet that Anthropic siphoned into their dataset belongs on the credits.
It's great that it happened, and I wish them the best of luck in using our work to make the world a better place. Just don't forget who the rightful owners are.
This is kind of meaningless. If Claude didn't do it then neither did any of the scientists credited on papers in the last...well ever. Everyone is standing on previous work.
The AI labs did that to themselves. All those billions and their marketing and communication skills are like those of a local street vendor selling fake knockoffs.
This is something I like joking around about, with regard to how LLMs are 'decent' [debatable but taken as a premise] software engineers. For a long time people have said DNA/RNA/etc is the programming of life.
If it is indeed HIGHLY analogous to programming, we would then expect LLMs/future systems to be HIGHLY proficient at accurate ex-vivo gene [or enzyme/protein] modification/construction
It is akin to programming but more complicated. In this case, you can run the same code on different systems and get different results, and this is in fact an advantage of the language as a whole. Same DNA throughout your entire body yet you have distinct cellular identities thanks to this ability.
But the hard part is really nothing is annotated or defined. We have annotated and defined some things but its tricky work and so much left to describe. Its like you have entered a house and have no idea what each room is for, or what the light switches do, or even what even is a light switch, or a room for that matter. Maybe you identify a repeated plastic switch through the building that seems to be nearby doorways, you call this the light switch. What does it do exactly? Have to flip it and hope you can detect what changed. Hopefully when you flip it the whole house doesn't just die in the womb, but actually limps along in some way where you can say "this switch controls the garage developing as an attached structure or detached in the back yard" Even more fun when the switch is just one piece of the circuit of a dozen plus switches that all have to flip a certain way in a certain order over a certain time for some function.
You will probably find this paper by Hessameddin Akhlaghpour very interesting: [An RNA-based theory of natural universal computation](https://pubmed.ncbi.nlm.nih.gov/34979104/).
I have bookmarked the links to read later but until then I would ask in what sense? To my knowledge the known physics currently is all within the realms of a Turing machine, which is equivalent to lambda calculus.
You can play with it. Equivalence with Turing machines is not the point of interest
Sorry about this "not A but B", now is one of those situations where is needed.
Is not:
- cellular automata,
- Turing machines
implemented chemically.
The goal, first of UPIM, then chemlambda or chemSKI, is simply to:
- find chemical complexes,
- or to make them
(though I suspect that we shall discover them in our cells)
so that they enter in random chemical reactions which are akin the graph rewriting inspired by lambda calculus or SKI combinators or Interaction Combinators.
The thesis is that this chemical translation still can do "anything" despite the lack of control of reactions or the combinatorial explosion of possible reaction networks.
It's really a matter of iterating on the problem and validation right?
Models make progress on coding and math because they can write tests and proofs to an extent. Many industries that are more 'physical' and require performing experiments lack that instant feedback loop. Find a way to close that loop and AI begins to look useful.
But try and convince companies to invest on closing that loop just to see if the current models work well on their problems or not? Tough sell.
So Anthropic just shows them, hey look, this is possible and if you don't do it I will.. so they fold.
>Models make progress on coding and math because they can write tests and proofs to an extent. Many industries that are more 'physical' and require performing experiments lack that instant feedback loop.
This is basically what they targeted with this approach. They can't automate the experiments since they are often bespoke towards certain goals or even feelings and assumptions based on sage technician knowledge that isn't really taught in any one place. Instead, they tried to automate the process of searching for candidate targets to then test in downstream lab experiments.
Seems exciting, but this sort of thing has been done for a while with just about every single ml classifier method out there for all sorts of biological data. Just yet another way to slice the pie.
I think you could make a corresponding argument about the unbounded complexities of an abstract domain like mathematics. Math also has a notorious reputation for difficulty. We don't even have a way to know how much there is to know about math.
I'm not sure I see one is clearly more difficult than the other.
Given enough time, I think anyone with a proclivity towards math could derive the quadratic formula from first principles. I don't think there's anything in biology that can really be derived in that way. You'd have to start from the physics of chemistry or something. In which case you'd need quantum mechanics and... math!
yes and no; you cant dump DNA in the context window and call it a day, in the blog post it was a common tool calling session. you do can have actual ml models for that, that the llm could use as a tool.
It's clear Dario believes that the solution to AI's PR problem is to cure cancer. Or invent other revolutionary medical treatments. They're going to heavily promote every step along the way no matter how small or far away from commercialization they are, like this one.
No doubt that curing cancer would help, but I think the timeline might be a little too long. Even RSI AGI will not be able to get new medical treatments to market instantly. Real world testing takes a long time and is an unavoidable part of the process.
Glad to hear how you feel about it. However, and this applies more generally than your comment above, what people online often forget is that there is such a thing as both positive and negative reinforcement. If you don’t reinforce positive behaviours as well as denouncing bad ones, then you don’t get good outcomes.
And reading my own comment back to myself, I realise I do this too, and fail to positively reinforce as much as denounce.
This is really cheap. Plenty of scientists, many of whom are my friends, are working very hard on finding new therapies for cancer, they were doing it before genomic models came along and still doing it now. The amount of times something in the media is lauded as "holy grail" that is never heard from again because it either only works in mice or turns out to be toxic or 100s of different reasons is massive. In my opinion this attitude of putting rose glasses, closing your ears and going "la la la AI is great can't do wrong" is detrimental to scientific progress. People outside of cancer research routinely underestimate how hard it is to find a working protocol. I think it is better to have sober attitude because it allows one to see the limitations and challenges that need to be tackled, blindly hoping AI can solve everything and deliver miracle cures is exactly the attitude that lets people sit on their asses and do nothing.
You can't say this. We have no idea. There is nothing about the law of physics that pushes cancer cure a long time away. A lot of people would have told you AI was decades away, yet here we are. We are still on track for possible strong take off.
Now on real world testing, you think the rule applies? I tell you it doesn't. Human life might be precious, but human life in practice is also not precious. We waste so much of it. In some countries regulations will stop/slow it, but there are plenty of places around the world that will turn a blind eye for a fistful of dollars. Countries will go to those locations if it means gaining an edge.
There are many things about the laws of physics that push a cancer cure a long time away! Biology is downstream of physics, and the biology of cancer is so vast that the very concept of a "cure for cancer" is almost nonsensical.
There's a lot about biology that makes cancer fundamentally hard to treat, and the efficacy of cancer treatments fundamentally hard to measure. I'm optimistic that we'll eventually get to a point where we can meaningfully say we "cured cancer", but it will almost certainly be a cluster of thousands of treatment protocols which each have to be tested over 5-10 years for recurrence. There's no reason to expect that there should exist any broad-spectrum cancer treatment better than radiotherapy, or any fast test to determine whether long-term remission.
Appeals to laws of physics as a "first principles" attempt to explain how thousands of diverse diseases could theoretically be solved overnight by a big computer (while hand waving away the years of clinical trials, false starts and failures involved in a single new successful treatment) just makes you seem wildly out of touch and uninformed about the actual problem space.
There are many laws of physics that say that cures for cancer- general ones that treat a wide array of cancers and are effectively permanent with no reoccurrence- are a long time away. Cancer is subtle. Cancer is wily. Cancer is tightly integrated with our eukaryotic nature.
AI was decades away, for decades! It took a wide range of conditions to be satisfied before it became clear it was a powerful tool.
Also, medical people rarely use the term "cure cancer", as we have too much experience with recurrence of the "same" cancer (not just in the same location, but a genetic descendent of the original cancer).
Yep, my prediction is that Anthropic is going to use Claude's reputation to "launder" known solutions to aging, cancer, and other things that society hasn't accepted quite yet. But maybe with the right marketing we'll try those things!
Its going to be an uphill battle. Every story about job losses, consequences to the community from building a datacenter (real or perceived), eminent domain case that blows up, plus all the slop on every platform. Not to mention a lot of normies think techbros are obnoxious, and that is who is hyping ai.
They'll need to show their goal is to help humanity and that all the other peoole arent acceptable collateral damage. Since those other people get to vote.
As they should because things like this get people thinking even if it something small. Once you get people thinking about things you tend to get solutions.
Also the general public might find the implications of AGI so distasteful even if everything goes well that we might stall out or get the Butlerian Jihad before we can cure cancer. Artists and Software Engineers, now also Mathematicians, already have existential crises, but the public still thinks AI is fake. I can't imagine the backlash when the realize what's coming even in the good ending.
Real world approvals for drugs are accelerating through, even with all the steps. Think about it, Moderna went from zero, to approved vaccine in 10 months. While COVID vaccines were the exception, not the rule, there are ways to accelerate the process if there is will and $$$. In the last 20 years, the number of new drug approvals per year in the US has doubled, and the length of time to get approval has been cut in half.
I'm not going to say that it is absolutely Earth shattering (not that they claim that), but your comment is obviously wrong. In the paper they show experimental results where they express some of the proteins and show a phenotypic effect. They don't claim an exact function either, and are relatively restrained on the biology end of things. I fail to see how it is at the level of a vague shower thought.
> Although we don’t yet know its function, the system that Claude discovered has a set of characteristics that have only ever been found together in a handful of other systems, all of which are programmable and perform operations like cutting, copying, and pasting DNA. Beyond CRISPR, which has already transformed science and medicine, several other such systems are now in development as promising tools.
It's not novel, and they don't know if it means anything. They published it here for PR purposes.
This to me reads like an absolutely bog standard statement that would be made at any university PR piece about any novel nucleic acid system like this one. The paper itself will usually be more restrained but still attempt to gain some status via comparison.
It also is clearly novel in the scientific sense. This is not a known system and it may resemble some attributes of similar systems but it differs substantially in its arrangement, since it's not clearly a retron.
As for if it is for PR. Yes, I don't disagree about that.
> Anthropic’s head of influencer, Lexie Barnhorn, has described creators as essential to building trust in complicated technical products. Its strategy is partly consumer-to-business: People who adopt Claude personally may later introduce it in their workplaces.
> Anthropic’s best-known creator events have been smaller dinners and pop-ups in which Claude remained the ostensible subject.
The point I am making is if these companies are going to compete and spend more and more money for PR, then they should do it in a way that benefits society, which paying influencers does not do.
Let me know when OpenAI starts actively trying to cure diseases.
Personally I feel like Anthropic is underrepresented in "normie" marketing, all of my non-tech savy friends only know of ChatGPT and use "ChatGPT" in the same way my mom says "Nintendo" when talking about game consoles
Aren't there unlimited mechanisms like this? Isn't this why Doudna isn't a billionaire (you can patent something, but it's easy to create another one and patent it separately)?
I run into this all the time - we have such powerful functionality available to our users, and further we provide the elements that undergird all of it, so it’s totally possible for clients to take the services they buy from us and reconfigure them to make their own tools, better even than the ones we have built, purpose-built for their workflows…
And 9/10 clients will just click on the one thing they know and recognize and are familiar with and comfortable with… and then stop thinking about it.
It’s crazy how much of our job is not only building our product, but interrogating our clients over what they need, so we can demonstrate how our tools solve their problem. The users simply are not interested in figuring it out for themselves.
This is my speculation as well. For the time being, knowing how to use Claude extremely effectively probably beats out industry insider status. And Anthropic can attract whatever expertise it needs to build scrappy research teams in house. I'm guessing this kind of work doesn't need 100+ people, maybe just a dozen highly specialized people.
Given the prestige of the AI labs, the recent explosion of math proofs, the literal millions they can throw around, it seems very likely they can attract then fund small research projects across a broad range of science. And like startup math, it only takes one or two ground breaking results from a hundred attempts to pay back in the PR/hype.
A chatbot for cancer researchers to talk to is worth single-digit billions at most. Anthropic is already valued at over a trillion dollars, on the premise that they can replace the majority of jobs in most knowledge industries. All the announcements about hacking / math problems / biological science are meant to create the impression that that strategy works and is repeatable across industries.
I was actually thinking the other day that it makes perfect sense for AI companies to develop a professional services oriented software development arm. Imagine that you want to develop a training pipeline for "tasteful" programming: you might make a reward metric for that does some obvious stuff (nothing that anyone could easily agree is a bug like a crash, good performance, perhaps minimize LoC), but you really want to also want to also track "bugs" where the feature was discovered to be missing some unspecified nuance that was only discovered through product use, or train on ability to keep a small codebase while also keeping diffs small (essentially, "maintainability") as real new requirements come in.
So then you want a training set full of real product requirements and product evolution, which is something you could get if you offered custom software development, with a lot more control than you'd get trying to do the same by scraping random FOSS projects on github.
Other industries are perhaps similar. If you offer a service directly, you have much more ability to build collection of training data into the process. Want to make the best law bot? Buy a law firm, offer legal services, and integrate extremely deeply into their workflows. If their models turn out to be as good as they hype up, they should be able to scale to be a major player in any endeavor they move into with a relatively small number of staff and develop a strong feedback loop (not that that would be good for the rest of us).
They do partner externally. This work is fundamental discovery science, rather than industrial research.
the folks who run anthropic grew up reading scifi with crazy awesome biotech. However, when they look at biotech today, it's just depressing. It's incredibly slow, it takes decadfes to prove out new technologies, and they figure with this new tool, they can just point it at problems and have it emit discoveries. If they show a few high-impact discoveries, that makes a case for them to move biotech forward much faster than its current progress.
Also, anthropic has so much capitalization right now that it's simply easiest to invest it in a wide portfolio that includes both internal and external research.
I think the "everything company" vision has become apparent for a while now. Doesn't even have to be sinister - I think Anthropic simply believes on one else can be trusted with this power. Another point of leverage they have is that they can keep their internal models for themselves.
> I’m confused why AI companies are using agents in-house for this type of research instead of partnering externally.
I am an outsider, but here is how I explain that behaviour.
1. Truly risky models are very useful
2. Truly risky models should not be released, according to AI safety standards. I think Antrhopic genuinely believes in AI safety. (see standing up against automated kill chain, no matter the impacts to the company)
3. Truly risky models face regulatory pressures, if released.
Lands as an active threat. Maybe they're serious about this research or not, but for sure medical companies doing this sort of research will consider upping their AI budget and connecting their labs, etc. to avoid "falling behind".
So, the AI labs benefit either from achieving something they could market or from the peer-pressure imposed to companies in the sectors they get their nose in.
I'm confused of why this is a question. First of all everyone is doing something because it benefits them. You and I included. Second of all as long as it's a real discovery, it will be beneficial to us all eventually (after benefiting Anthropic for sure).
Perhaps you're not on HN long enough, but there have been many posts where someone bemoaned the lack of basic science research by corporations, that IBM and Microsoft were the only a few remaining companies with any science research. Guess what? they do it for their own benefits as well.
Because as I see it, there are a lot of already established labs that could take research like this a lot further with the help of AI instead of just throwing more agents at the problem.
That’s my confusion around this topic. Does the strategy change when you can throw a bonkers amount of compute at the problem with fewer guardrails?
Because you're not understanding the goal. The goal isn't to assist humans in making the discovery. The goal is to develop a system that can autonomously make the discoveries, as this is way more scalable.
There are so many people involved on this yet we still say things like "Claude did", we need to start waking up and being more real about how we are still in "AI + Human" land.
What's wrong with saying "A team of researchers backed by Anthropic using Claude discovers a novel enzyme system with CRISPR-like repeats" or, ffs, mention the lead researcher in the headline?
I'm more annoyed that they announce "CRISPR-like" to hit those SV Next Big Thing dopamine receptors but upon reading haven't done any laboratory work to determine if it has any useful applications like CRISPR-Cas9.
It's totally legitimate research worthy of publication, but Anthropic chose a hot technology in the popular imagination for a reason. Now I'm going to have to see "Claude invented a new CRISPR in 24 hours!" everywhere and trying to correct it will just turn into repetitive arguments about goalposts moving....
It looks like the researchers just wrote the agentic harness and the rest of the work really was done autonomously by Claude with only extremely limited guidance after.
BTW the first author of the paper worked in the Doudna lab studying the origins of crispr (and after their PhD, joined Anthropic). All of the authors either have, or are going to have, excellent careers. I dont' think they are worried about attribution.
Anthropic is paying them to not worry that much about attribution. If any of them emphasised their role over and above Claude they wouldn't get the money anymore.
At a trade show, I met a company that was advertising a feature as powered by Claude. I asked an employee what that meant, as it seemed unlikely, and he then didn’t know how answer so he introduced me to the CEO. The CEO said that the ad meant that Claude now writes all of their code including that new feature. They are now working on having Claude handle their QA process. I wondered if any of the devs were at the booth or if the employee I spoke to first was a dev who knew it was bs.
I wish we could discuss this in a way that didn't immediately devolve into people shouting up or shouting down that this is either meaningless or singularity.
Caveating I'm not a biologist, but my understanding of the way this kind of thing works right now is a basic three-step process:
1) Find molecules and DNA/RNA sequences in the wild and catalog them.
2) Discover interesting subsequences among these.
3) Figure out whether any useful applications can come from what was discovered.
All three of these generally take a long time. Systematic automatic analysis of known databases speeds up and removes some of the luck from 2. But 1 and 3 are still long poles. 1 has the further issue that we usually discover these in existing organisms. I recall much of the outcry over tropical deforestation back in the 90s and replacing of rainforests with palm oil monoculture today is that the vast majority of terrestrial biodiversity is found in rainforests, and destroying them at industrial scale risks losing potentially useful molecules forever. 3 has the problem that you need to conduct physical experiments, and are limited by the speed of biochemical reactions no matter what and by the speed at which human subjects can be found and ethically experimented on assuming we care about being ethical.
A lot of good can come of this, but I don't see a path to singularity here, assuming we're talking the original Kurzweil meaning there of all technological progress that will ever happen all happening at once. Data collection and experimentation on living subjects, human or not, can only happen so fast, regardless of automation. It's not computational. Whenever you have to interface with the real world, you're now working at the speed of the real world, not the speed of electricity. CRISPR was discovered in 1987 and first used to edit a gene sequence in a human zygote in 2015. I'm sure there are plenty of ways to make the candidate discovery to human application step not take three decades, but it's never going to be three months, either.
I agree, this is a cool result, but not something far out or extremely novel. It's discovering a new class of things that is different from other similar things we already knew about. One of those similar things we already knew about (CRISPER) turned out to be better than other tools we have for editing DNA in vivo, so that makes it potentially more exciting, but others haven't had the same application. It's interesting because the function is unknown, and you're right there's a lot of followup to figure out just exactly what is going on and why, much less to come up with an idea for how to use it to do something cool.
To me this strikes me as an incremental discovery that would have taken someone with time, interest, and expertise to make before. It could have cool applications or it could just be interesting biology. Molecular biology has progressed through many years and many rounds of automation and new tools, but the problems are still hard. This just strikes me as one more way we may be able to speed up one part of the process.
Thank you for sharing, that provided some good context for how to interpret this
Post content:
_____
I wish we didn’t need these again, but here is the honest version of Anthropic’s biology announcement
(Caveat: I haven’t worked in bioinformatics for many years.)
The good: Anthropic ran ~950 Claude agents over a large biological sequence database. Claude searched, wrote code, compared sequences and genomic neighborhoods, and found an interesting pattern that apparently had not been noticed before: a known reverse transcriptase associated with another gene and a repetitive DNA array.
That is cool. Automating this kind of open-ended bioinformatics search at scale is useful, and Claude may have found a lead a human would have missed.
But: Claude did not do a biological experiment. It searched databases and analyzed data.
Humans then took the candidate into the wet lab. And the wet-lab result so far is modest: they showed that the repeat array produces short RNAs.
We still don’t know what the system does. No function, mechanism, phenotype, targeting, defense activity, or programmability has been demonstrated.
This is also where the CRISPR framing gets ahead of the result. Right now, “it has some features reminiscent of known programmable systems” is a hypothesis for what to investigate next, not a discovery that it behaves like CRISPR.
And there is a missing baseline: bioinformatics has had tools for finding unusual gene neighborhoods and candidate systems for years. The interesting comparison is 950 Claude agents vs. an expert using the best existing computational pipelines - not Claude vs. someone manually looking through 200,000 sequences.
So my honest announcement would be:
Claude autonomously found an interesting candidate for a previously uncharacterized biological system. A small human wet-lab experiment confirmed that part of the candidate is expressed. We don’t yet know what it does.
That is a good result.
But in a regular biology lab, this isn’t the finished paper. It is the result you show at lab meeting and say: “This looks interesting. Now we need to figure out what the hell it does.”
Maybe that next step leads to a major discovery. But that discovery hasn’t happened yet.
He was a PhD student. He knows the significance level of this result. He knows that if he had walked into Bill’s office (his advisor) with “we found an interesting system, but we still don’t know what it does” and said he was ready to graduate, Bill would have kicked him out of the room.
But somehow, when the IPO is around the corner, this becomes “AI is starting to drive biological discovery.”
I am irked by the CRISPR framing. That seems to be IPO positioning.
Speaking from experience, good hypotheses are a dime a dozen in life sciences. Biology is very unforgiving and most hypotheses lead to nothing when thoroughly tested. This is true for something as "simple" as enzymes as in this case, but even more true for curing diseases. Otherwise, there would not be any failures of phase III clinical trials, after billions USD spent on preclinical research and prior clinical trials.
When overinterpreting these (interesting) results, you are entering Andy Grove Fallacy [0] territory very fast.
100% AI per Pangram. I caught it at "This is also where the CRISPR framing gets ahead of the result." -- somehow this is not a sentence anybody non-obnoxious would write. It's a weird structure where the AI talks about something specific as if it were an example of a common theme. This paragraph is an even clearer ekample:
"But in a regular biology lab, this isn’t the finished paper. It is the result you show at lab meeting and say: “This looks interesting. Now we need to figure out what the hell it does.”"
While I agree with you that this is likely AI assisted, I think this may be changing now.
People speak in the manner of what they consume. If you consume a lot of claudish, you will eventually start talking claudish too. And I've already noticed people talking claudish in real life.
I had to check and he does not seem to have the real qualifications to make his comments. In particular, he did computational neuro, not bioinformatics, and I can't find publications to support his claim.
They're publishing press releases about "novel discoveries" done with their A.I. all the time to pump up their share price. When you look closely it's very minor stuff.
Like that story about their A.I. "escaping" its sandbox and hacking other companies. Purely to instill the idea that it's intelligent and has a will of its own.
It wouldn't even surprise me if behind every prompt you type some Indian in a sweatshop is typing the response.
If by now you still think it's all just hype, it's safe to say you've succumbed to a mind virus that renders you unable to think critically about AI. Otherwise you'd have some level of awareness of just how far this technology has developed, and you should find these developments more than plausible.
A.I. is an extremely broad term. I'm not convinced that the capabilities of these LLMs are what they claim them to be.
That's not to say that advances in machine intelligence can't lead to something that's truly useful or even groundbreaking. I'm just saying that the current technology isn't that and I therefore call it a hype.
It is odd (or maybe not) that they decided to publish a marketing whitepaper rather than a more traditional journal submission + preprint. The work does appear to be sufficient for a publication, though there's a good chance a reviewer will rip into them for some of the assertions they make, but given the topic I'm sure the paper will be accepted regardless.
The market for entry-level programmers has already declined, but at least they were somewhat in demand and made reasonable salaries. Now what happens to post-docs who already make almost nothing and often get treated like crap?
I see all of this leading to a setup for: We did cure Cancer, everyone else (Healthcare, Gov., Rx) etc... has just not caught up or even worse; "you just don't have access top that model/version".
I have seen several times on HN recently how people don't see the impact of AI/more code etc... and I believe this is because its following the K-shape of the current economy.
At the top where most of us aren't but CAN see via stock market news etc...; they are making more money by adding efficiencies etc...
At the bottom; efficiencies are being applied at a scale that they could not before such that social and Gov. programs are more manageable and optimized at scale.
Did anyone read the blogpost? They did publish a pre-print:
> Our work to understand the primary function of ARTs is ongoing. However, we think it is important to share such findings early, both to demonstrate Claude’s capabilities and to give the broader community insight into what we’re working on. We have released a pre-print (here) that discusses this in more detail.
What's with all this pre-print business. It became very prevalent during covid, where it felt like every week some new pre-print was published that discusses some new aspect of the virus. These papers would then be used in arguments and put forward as proof of whatever claim the arguer was making.
Every man and his dog can publish a pre-print and in my opinion it's academically worthless.
The review time on top journals is multiple years now (your paper will go through many review loops each of which takes months). It's just totally unworkable for active research, whether you're a student or a corporation.
Preprints are just a way to sacrifice rigor for accessibility and velocity. You can throw out "here, this is what I'm working on, here are the quick and dirty findings" really fast and with little friction.
This does skip the academic "checks and balances" like journal selection and peer review - but it can also help anyone else who's working on the adjacent topics.
If a field is moving fast, and you think there can be some value in your work for others in the near term? Preprint. If your work is too incomplete or too minor to warrant trying to polish and publish it, but you don't want to table it? Preprint. Too deep in corporate structures to care about academic "street cred", and want your work to be accessible? Preprint. Have an exciting early finding that you want to push out there, and are willing to take the rep risks of being wrong about it? Preprint.
There's a reason why preprints came to be the lifeblood of ML.
Academia isn't my thing but I also wonder if there isn't an aspect of putting a stake in the ground? So that if someone beats you to publishing you at least have some record of being on that track.
That is definitely a big motivator for publishing preprints. Journal submissions can take up to a year. Comference submissions take months. If the field is moving fast, claiming a finding early can become an important career move.
In older days, academics would just share notes on their work and word wouldn't usually spread widely before publication.
Preprints may be the better model. But public visibility means that non-experts now get to see the good and the bad research equally, but they won't have the domain knowledge and skill to distinguish one from the other with confidence.
I have a similar to pagerank method I use to evaluate such papers. I look for the references to see how many authors are using their own references (past work), the idea being that people do not jump too far, they make incremental progress.
For the pre-print I could only find only one author who has a single referenced article.
> references to see how many authors are using their own references (past work), the idea being that people do not jump too far, they make incremental progress
The authors are not using their own prior work in the paper, thats the point I was trying to make. I have worked in biotech lab for couple years and its one of the criteria's people use to consider some ones work useful and worth the time.
I think you fundamentally misunderstand both the results published here, and how scientists operating at the highest level of academic research operate. None of these authors has to worry about citing previous work to get the attention of biotech labs.
The link was there from the start. Perhaps you were just looking for something to criticize. And now you've moved the goalposts to "they've posted it to their own domain."
I just looked at it. I really hope they're not thinking of sending that to an actual bioinformatics, computational biology or molecular biology journal! So embarrassing...
(I love how Anthropic boast about building a lab, but don't seem to realise that you have to test your hypothesis in the lab! Right now, all their "spectacular" assertions are untested and unproven.)
I realise that this will only improve from here, but gods Anthropic has no idea about the biological sciences right now.
Um. Take a look at the authors. Every single one of them is an expert in this field. They did test this in a lab.
If you want to complain about things like this, it really helps to be specific. Given the author list, it's unlikely they made any truly spectacular errors (and also possible the system they studied is not interesting).
Can you elaborate on what you're thinking? I don't see any support for this being a hallucaination; from what I can see, it's a pretty typical "early biological discovery".
I was poking fun at evolarjun and epihelix for "hallucinating" that this was just a marketing whitepaper (they did publish a pre-print) and that the preprint was "so embarrassing" (you said that the authors are actually experts). It kind of seemed like they had some opinion about AI and this paper, and wishfully concluded things that were not true to support their opinion.
> The market for entry-level programmers has already declined, but at least they were somewhat in demand and made reasonable salaries. Now what happens to post-docs who already make almost nothing and often get treated like crap?
Waiting for frontier labs to get into Political Science to show that SOTA models can be vastly better politicians...
It's not odd at all. Every single "AI did this cool thing" type post is an Ad. Remember AI outputs slop and never produced anything valuable that wasn't heavily assisted by humans or is a lie.
> Now what happens to post-docs who already make almost nothing and often get treated like crap?
This sort of discoveries are what gets postdocs funded lmao.
Every new idea like this creates several years worth of highly specialized work to test out derivative ideas, productizing it, and connecting dots to existing work.
Why do you think they're going to be treated badly? Right now, I think it's kinda accepted that the people best suited to directing AI for programming tasks are programmers - only we operate at a higher level.
Claude's going to be a similar productivity booster to researchers and postdocs.
I'd be totally lost talking to an AI about biochemistry.
I recently heard Anthropic quietly setup its own bio lab.
That it’s plausible that they’ll move from selling tokens as their primary source of revenue to building frontier models to do cutting edge research, and using the research as their primary source of revenue rather than release the models. Because it’ll be far less of a race to the bottom than commodified tokens used by the general public.
Will be interesting to see how this all unfolds. (No pun intended, but there is a funny one there…)
apparently big labs are also pitching profit sharing arrangements to biopharma companies in exchange for privileged access to the top internal above-the-api capability models .... repeat this in every industrial vertical and it could turn out that much denied Dario claim may as well have been true for all intents and purposes
I mean its what universities have done for years haven't they?
Never really wondered what financial relationship between research hospitals that participate in drug trials and pharma companies is, but now I'm wondering...
Yea, I think that there's pretty much a ceiling with day-to-day models that have already been hit months ago. Maybe you need SOTA for reviews, high-level planning, or research, but long running tasks like writing out a feature, testing, getting feedback and making refactors can be done for low-end models (like luna). And the margins on those models are basically evaporating.
"We gave Claude a prompt to search through a massive database of DNA sequences for interesting new examples of RTs. Our involvement was limited to the initial prompt and the lab work, while Claude agents combed through the database, investigated the distinct RT families, and used their own judgement to identify interesting candidates. After 21 hours spent searching this data by roughly 950 agents using 210 million tokens, one of the agents spotted something remarkable: a repeating pattern of DNA sequences that occurs next to the gene for an odd-looking RT. After further analysis and testing in our lab, we recognized that this pattern marked a previously uncharacterized enzyme system found in bacteriophages (the viruses that infect bacteria) that we call array-associated reverse transcriptases (ART)."
It isn't a convenient gotcha. It's about what the people pushing the given thing are intending.
Person demoing something they made is usually trying to hide the fact they had claude built it and sell it like they didn't. This sort of person often lacks the technical skills to vet that what claude actually produced is actually working as they expect. Hence the snark.
On the other hand, with anthropic's case, they are trying to say "claude did this, how smart it is" while trying to downplay the fact that they needed it to be steered by domain experts to produce anything worthwhile.
This framing overlooks an unstated caveat - i.e. people that work for an LLM company have an incentive to minimize human contribution as much as possible in their narratives.
462 comments
[ 0.21 ms ] story [ 90.6 ms ] thread> All of the lab work is performed by human scientists.
Not saying that they were right or wrong, but that single moment sullied all AI-driven breakthroughs that came after it, and I don't think it was ever particularly relevant, at least not nearly to the degree that it was presented in the media. But I guess it ended up being a convenient outlet for AI anxiety in the end.
The LLMs that make this stuff possible weren't created by the AI labs from whole cloth. They crept up and jumped onto the shoulders of giants, basically the collected (non-consensually, of course, but jingles keys look at this pelican riding a bicycle!) works of humanity. Every discovery LLMs enumerate in this fashion rightfully needs to have a billboard-sized asterisk regarding the provenance of the discovery. "Claude" didn't discover this, everyone who worked to produce the internet that Anthropic siphoned into their dataset belongs on the credits.
It's great that it happened, and I wish them the best of luck in using our work to make the world a better place. Just don't forget who the rightful owners are.
All it takes is to identify the syntax, so to say.
If it is indeed HIGHLY analogous to programming, we would then expect LLMs/future systems to be HIGHLY proficient at accurate ex-vivo gene [or enzyme/protein] modification/construction
But the hard part is really nothing is annotated or defined. We have annotated and defined some things but its tricky work and so much left to describe. Its like you have entered a house and have no idea what each room is for, or what the light switches do, or even what even is a light switch, or a room for that matter. Maybe you identify a repeated plastic switch through the building that seems to be nearby doorways, you call this the light switch. What does it do exactly? Have to flip it and hope you can detect what changed. Hopefully when you flip it the whole house doesn't just die in the womb, but actually limps along in some way where you can say "this switch controls the garage developing as an attached structure or detached in the back yard" Even more fun when the switch is just one piece of the circuit of a dozen plus switches that all have to flip a certain way in a certain order over a certain time for some function.
And a [YouTube talk by the author](https://www.youtube.com/watch?v=984vm12HUF0).
Sorry about this "not A but B", now is one of those situations where is needed.
Is not:
- cellular automata, - Turing machines
implemented chemically.
The goal, first of UPIM, then chemlambda or chemSKI, is simply to: - find chemical complexes, - or to make them
(though I suspect that we shall discover them in our cells)
so that they enter in random chemical reactions which are akin the graph rewriting inspired by lambda calculus or SKI combinators or Interaction Combinators.
The thesis is that this chemical translation still can do "anything" despite the lack of control of reactions or the combinatorial explosion of possible reaction networks.
Under this thesis we are graph quines.
Models make progress on coding and math because they can write tests and proofs to an extent. Many industries that are more 'physical' and require performing experiments lack that instant feedback loop. Find a way to close that loop and AI begins to look useful.
But try and convince companies to invest on closing that loop just to see if the current models work well on their problems or not? Tough sell. So Anthropic just shows them, hey look, this is possible and if you don't do it I will.. so they fold.
This is basically what they targeted with this approach. They can't automate the experiments since they are often bespoke towards certain goals or even feelings and assumptions based on sage technician knowledge that isn't really taught in any one place. Instead, they tried to automate the process of searching for candidate targets to then test in downstream lab experiments.
Seems exciting, but this sort of thing has been done for a while with just about every single ml classifier method out there for all sorts of biological data. Just yet another way to slice the pie.
We can barely inspect much of it, let alone fully understand it.
I'm not sure I see one is clearly more difficult than the other.
No doubt that curing cancer would help, but I think the timeline might be a little too long. Even RSI AGI will not be able to get new medical treatments to market instantly. Real world testing takes a long time and is an unavoidable part of the process.
And reading my own comment back to myself, I realise I do this too, and fail to positively reinforce as much as denounce.
Now on real world testing, you think the rule applies? I tell you it doesn't. Human life might be precious, but human life in practice is also not precious. We waste so much of it. In some countries regulations will stop/slow it, but there are plenty of places around the world that will turn a blind eye for a fistful of dollars. Countries will go to those locations if it means gaining an edge.
AI was decades away, for decades! It took a wide range of conditions to be satisfied before it became clear it was a powerful tool.
Also, medical people rarely use the term "cure cancer", as we have too much experience with recurrence of the "same" cancer (not just in the same location, but a genetic descendent of the original cancer).
https://news.ycombinator.com/item?id=49329717
He isn’t wrong. But selling potential cures for cancer won’t cut it.
They'll need to show their goal is to help humanity and that all the other peoole arent acceptable collateral damage. Since those other people get to vote.
Generally speaking, hiring an army of influencers to shill for you results in bad PR, and comments like this one.
It's not novel, and they don't know if it means anything. They published it here for PR purposes.
It also is clearly novel in the scientific sense. This is not a known system and it may resemble some attributes of similar systems but it differs substantially in its arrangement, since it's not clearly a retron.
As for if it is for PR. Yes, I don't disagree about that.
Is there an equivalent headline for Anthropic of this?: https://www.businessinsider.com/inside-open-ai-influencer-ma...
https://www.businessinsider.com/emma-orhun-canceled-claude-p...
> Anthropic’s head of influencer, Lexie Barnhorn, has described creators as essential to building trust in complicated technical products. Its strategy is partly consumer-to-business: People who adopt Claude personally may later introduce it in their workplaces.
> Anthropic’s best-known creator events have been smaller dinners and pop-ups in which Claude remained the ostensible subject.
Let me know when OpenAI starts actively trying to cure diseases.
I guess the improvement loop is tighter and they have more control over how discoveries can be used for marketing?
But, in my mind, it begins to feel like they are setting themselves up to be “everything” companies instead of focusing on their core product…
I run into this all the time - we have such powerful functionality available to our users, and further we provide the elements that undergird all of it, so it’s totally possible for clients to take the services they buy from us and reconfigure them to make their own tools, better even than the ones we have built, purpose-built for their workflows…
And 9/10 clients will just click on the one thing they know and recognize and are familiar with and comfortable with… and then stop thinking about it.
It’s crazy how much of our job is not only building our product, but interrogating our clients over what they need, so we can demonstrate how our tools solve their problem. The users simply are not interested in figuring it out for themselves.
Given the prestige of the AI labs, the recent explosion of math proofs, the literal millions they can throw around, it seems very likely they can attract then fund small research projects across a broad range of science. And like startup math, it only takes one or two ground breaking results from a hundred attempts to pay back in the PR/hype.
I am disappointed by your lack of Capitalism buff. What you say is true, but what is the untapped fetish market for such a thing?
I don't think replacing the majority of jobs in knowledge is priced in at a 1T valuation.
So then you want a training set full of real product requirements and product evolution, which is something you could get if you offered custom software development, with a lot more control than you'd get trying to do the same by scraping random FOSS projects on github.
Other industries are perhaps similar. If you offer a service directly, you have much more ability to build collection of training data into the process. Want to make the best law bot? Buy a law firm, offer legal services, and integrate extremely deeply into their workflows. If their models turn out to be as good as they hype up, they should be able to scale to be a major player in any endeavor they move into with a relatively small number of staff and develop a strong feedback loop (not that that would be good for the rest of us).
https://www.reuters.com/world/anthropic-quietly-sets-up-biol...
the folks who run anthropic grew up reading scifi with crazy awesome biotech. However, when they look at biotech today, it's just depressing. It's incredibly slow, it takes decadfes to prove out new technologies, and they figure with this new tool, they can just point it at problems and have it emit discoveries. If they show a few high-impact discoveries, that makes a case for them to move biotech forward much faster than its current progress.
Also, anthropic has so much capitalization right now that it's simply easiest to invest it in a wide portfolio that includes both internal and external research.
I am an outsider, but here is how I explain that behaviour.
1. Truly risky models are very useful
2. Truly risky models should not be released, according to AI safety standards. I think Antrhopic genuinely believes in AI safety. (see standing up against automated kill chain, no matter the impacts to the company)
3. Truly risky models face regulatory pressures, if released.
So, the AI labs benefit either from achieving something they could market or from the peer-pressure imposed to companies in the sectors they get their nose in.
Aren't all large companies like that? Apple makes hardware, software, platforms, ...
Perhaps you're not on HN long enough, but there have been many posts where someone bemoaned the lack of basic science research by corporations, that IBM and Microsoft were the only a few remaining companies with any science research. Guess what? they do it for their own benefits as well.
Because as I see it, there are a lot of already established labs that could take research like this a lot further with the help of AI instead of just throwing more agents at the problem.
That’s my confusion around this topic. Does the strategy change when you can throw a bonkers amount of compute at the problem with fewer guardrails?
There are so many people involved on this yet we still say things like "Claude did", we need to start waking up and being more real about how we are still in "AI + Human" land.
What's wrong with saying "A team of researchers backed by Anthropic using Claude discovers a novel enzyme system with CRISPR-like repeats" or, ffs, mention the lead researcher in the headline?
It's totally legitimate research worthy of publication, but Anthropic chose a hot technology in the popular imagination for a reason. Now I'm going to have to see "Claude invented a new CRISPR in 24 hours!" everywhere and trying to correct it will just turn into repetitive arguments about goalposts moving....
BTW the first author of the paper worked in the Doudna lab studying the origins of crispr (and after their PhD, joined Anthropic). All of the authors either have, or are going to have, excellent careers. I dont' think they are worried about attribution.
I think "just" and "harness" are carrying a lot there, you likely underestimate how much that matters and how their knowledge made it possible
Caveating I'm not a biologist, but my understanding of the way this kind of thing works right now is a basic three-step process:
1) Find molecules and DNA/RNA sequences in the wild and catalog them.
2) Discover interesting subsequences among these.
3) Figure out whether any useful applications can come from what was discovered.
All three of these generally take a long time. Systematic automatic analysis of known databases speeds up and removes some of the luck from 2. But 1 and 3 are still long poles. 1 has the further issue that we usually discover these in existing organisms. I recall much of the outcry over tropical deforestation back in the 90s and replacing of rainforests with palm oil monoculture today is that the vast majority of terrestrial biodiversity is found in rainforests, and destroying them at industrial scale risks losing potentially useful molecules forever. 3 has the problem that you need to conduct physical experiments, and are limited by the speed of biochemical reactions no matter what and by the speed at which human subjects can be found and ethically experimented on assuming we care about being ethical.
A lot of good can come of this, but I don't see a path to singularity here, assuming we're talking the original Kurzweil meaning there of all technological progress that will ever happen all happening at once. Data collection and experimentation on living subjects, human or not, can only happen so fast, regardless of automation. It's not computational. Whenever you have to interface with the real world, you're now working at the speed of the real world, not the speed of electricity. CRISPR was discovered in 1987 and first used to edit a gene sequence in a human zygote in 2015. I'm sure there are plenty of ways to make the candidate discovery to human application step not take three decades, but it's never going to be three months, either.
To me this strikes me as an incremental discovery that would have taken someone with time, interest, and expertise to make before. It could have cool applications or it could just be interesting biology. Molecular biology has progressed through many years and many rounds of automation and new tools, but the problems are still hard. This just strikes me as one more way we may be able to speed up one part of the process.
https://x.com/ziv_ravid/status/2102844800345251858
Post content:
_____
I wish we didn’t need these again, but here is the honest version of Anthropic’s biology announcement (Caveat: I haven’t worked in bioinformatics for many years.) The good: Anthropic ran ~950 Claude agents over a large biological sequence database. Claude searched, wrote code, compared sequences and genomic neighborhoods, and found an interesting pattern that apparently had not been noticed before: a known reverse transcriptase associated with another gene and a repetitive DNA array.
That is cool. Automating this kind of open-ended bioinformatics search at scale is useful, and Claude may have found a lead a human would have missed.
But: Claude did not do a biological experiment. It searched databases and analyzed data.
Humans then took the candidate into the wet lab. And the wet-lab result so far is modest: they showed that the repeat array produces short RNAs.
We still don’t know what the system does. No function, mechanism, phenotype, targeting, defense activity, or programmability has been demonstrated.
This is also where the CRISPR framing gets ahead of the result. Right now, “it has some features reminiscent of known programmable systems” is a hypothesis for what to investigate next, not a discovery that it behaves like CRISPR.
And there is a missing baseline: bioinformatics has had tools for finding unusual gene neighborhoods and candidate systems for years. The interesting comparison is 950 Claude agents vs. an expert using the best existing computational pipelines - not Claude vs. someone manually looking through 200,000 sequences.
So my honest announcement would be:
Claude autonomously found an interesting candidate for a previously uncharacterized biological system. A small human wet-lab experiment confirmed that part of the candidate is expressed. We don’t yet know what it does.
That is a good result.
But in a regular biology lab, this isn’t the finished paper. It is the result you show at lab meeting and say: “This looks interesting. Now we need to figure out what the hell it does.”
Maybe that next step leads to a major discovery. But that discovery hasn’t happened yet.
> The sad thing is that Dario knows better.
He was a PhD student. He knows the significance level of this result. He knows that if he had walked into Bill’s office (his advisor) with “we found an interesting system, but we still don’t know what it does” and said he was ready to graduate, Bill would have kicked him out of the room.
But somehow, when the IPO is around the corner, this becomes “AI is starting to drive biological discovery.”
Speaking from experience, good hypotheses are a dime a dozen in life sciences. Biology is very unforgiving and most hypotheses lead to nothing when thoroughly tested. This is true for something as "simple" as enzymes as in this case, but even more true for curing diseases. Otherwise, there would not be any failures of phase III clinical trials, after billions USD spent on preclinical research and prior clinical trials.
When overinterpreting these (interesting) results, you are entering Andy Grove Fallacy [0] territory very fast.
[0] https://www.science.org/content/blog-post/andy-grove-rich-fa...
"But in a regular biology lab, this isn’t the finished paper. It is the result you show at lab meeting and say: “This looks interesting. Now we need to figure out what the hell it does.”"
This is not how people write!
While I agree with you that this is likely AI assisted, I think this may be changing now.
People speak in the manner of what they consume. If you consume a lot of claudish, you will eventually start talking claudish too. And I've already noticed people talking claudish in real life.
This A.I. hype makes the Internet Bubble look like a walk in the park.
Like that story about their A.I. "escaping" its sandbox and hacking other companies. Purely to instill the idea that it's intelligent and has a will of its own.
It wouldn't even surprise me if behind every prompt you type some Indian in a sweatshop is typing the response.
That's not to say that advances in machine intelligence can't lead to something that's truly useful or even groundbreaking. I'm just saying that the current technology isn't that and I therefore call it a hype.
The market for entry-level programmers has already declined, but at least they were somewhat in demand and made reasonable salaries. Now what happens to post-docs who already make almost nothing and often get treated like crap?
I see all of this leading to a setup for: We did cure Cancer, everyone else (Healthcare, Gov., Rx) etc... has just not caught up or even worse; "you just don't have access top that model/version".
I have seen several times on HN recently how people don't see the impact of AI/more code etc... and I believe this is because its following the K-shape of the current economy.
At the top where most of us aren't but CAN see via stock market news etc...; they are making more money by adding efficiencies etc...
At the bottom; efficiencies are being applied at a scale that they could not before such that social and Gov. programs are more manageable and optimized at scale.
Every man and his dog can publish a pre-print and in my opinion it's academically worthless.
This does skip the academic "checks and balances" like journal selection and peer review - but it can also help anyone else who's working on the adjacent topics.
If a field is moving fast, and you think there can be some value in your work for others in the near term? Preprint. If your work is too incomplete or too minor to warrant trying to polish and publish it, but you don't want to table it? Preprint. Too deep in corporate structures to care about academic "street cred", and want your work to be accessible? Preprint. Have an exciting early finding that you want to push out there, and are willing to take the rep risks of being wrong about it? Preprint.
There's a reason why preprints came to be the lifeblood of ML.
In older days, academics would just share notes on their work and word wouldn't usually spread widely before publication.
Preprints may be the better model. But public visibility means that non-experts now get to see the good and the bad research equally, but they won't have the domain knowledge and skill to distinguish one from the other with confidence.
For the pre-print I could only find only one author who has a single referenced article.
Pagerank was inspired by academic citation networks; it just turned it in a recursive matrix problem (of which there was some prior literature).
The authors are not using their own prior work in the paper, thats the point I was trying to make. I have worked in biotech lab for couple years and its one of the criteria's people use to consider some ones work useful and worth the time.
(I love how Anthropic boast about building a lab, but don't seem to realise that you have to test your hypothesis in the lab! Right now, all their "spectacular" assertions are untested and unproven.)
I realise that this will only improve from here, but gods Anthropic has no idea about the biological sciences right now.
If you want to complain about things like this, it really helps to be specific. Given the author list, it's unlikely they made any truly spectacular errors (and also possible the system they studied is not interesting).
Waiting for frontier labs to get into Political Science to show that SOTA models can be vastly better politicians...
This sort of discoveries are what gets postdocs funded lmao.
Every new idea like this creates several years worth of highly specialized work to test out derivative ideas, productizing it, and connecting dots to existing work.
Claude's going to be a similar productivity booster to researchers and postdocs.
I'd be totally lost talking to an AI about biochemistry.
> Startup aims for Claude AI to direct robots in lab environments, one source says
> Company to stop short of clinical trials to avoid drugmaker competition, life sciences head says
https://www.reuters.com/world/anthropic-quietly-sets-up-biol...
no mention of opus/mythos/fable or anything..
That it’s plausible that they’ll move from selling tokens as their primary source of revenue to building frontier models to do cutting edge research, and using the research as their primary source of revenue rather than release the models. Because it’ll be far less of a race to the bottom than commodified tokens used by the general public.
Will be interesting to see how this all unfolds. (No pun intended, but there is a funny one there…)
Never really wondered what financial relationship between research hospitals that participate in drug trials and pharma companies is, but now I'm wondering...
- a person demoing something they made
- a demonstration of something achieved with the assistance of llmsPerson demoing something they made is usually trying to hide the fact they had claude built it and sell it like they didn't. This sort of person often lacks the technical skills to vet that what claude actually produced is actually working as they expect. Hence the snark.
On the other hand, with anthropic's case, they are trying to say "claude did this, how smart it is" while trying to downplay the fact that they needed it to be steered by domain experts to produce anything worthwhile.
AI hacked a system. Humans did it.
If someone shares something "Claude did", they get the opposite.
You can't win.